RxDoctor Payments Data

Lewis Kline, MD

Pulmonary Disease · Pittsburgh, PANPI 1508868241

Payments from drug & device makers

$99,007in general payments, 2019–2025

Across 105 payments — averaging $942.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$81K
  • Breathe Technologies, Inc.$17K
  • Grifols Shared Services North America, Inc.$816
  • GSK$44
  • Harmony Biosciences LLC$37
  • Philips North America LLC$19

What the payments were for

  • Speaking & faculty fees$73,69374%
  • Travel & lodging$6,3426%
  • Food & beverage$2,0912%
  • Ownership interest$16,88217%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Grifols USA, LLC95$81,209
Breathe Technologies, Inc.2$16,882
Grifols Shared Services North America, Inc.3$816
GSK2$44
Harmony Biosciences LLC2$37
Philips North America LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,007 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$27,490
Medicare patients
248
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor28$418,998
UptraviSelexipag11$153,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter212$150,728
Dupixent SyringeDupilumab17$65,718
XolairOmalizumab16$55,487
Breo ElliptaFluticasone/Vilanterol75$32,786
Stiolto RespimatTiotropium Br/Olodaterol Hcl32$17,265
Spiriva RespimatTiotropium Bromide15$12,704
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$10,681
Modafinil110$10,500
SymbicortBudesonide/Formoterol Fumarate18$6,089
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$4,141
Albuterol Sulfate HfaAlbuterol Sulfate109$3,188
Azelastine Hcl104$2,734
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$81,209$418,99828 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$44$194,195308 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →